Amgen Inc. closed $84.79 short of its 52-week high ($346.85), which the company achieved on July 25th.

Neither coffee drinking pattern was tied to more or less cancer-specific mortality.

Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...

Investors should also pay attention to any latest changes in analyst estimates for Amgen. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, ...

Truist lowered the firm’s price target on Amgen (AMGN) to $298 from $333 and keeps a Hold rating on the shares as part of a broader research ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Hold rating on Amgen (AMGN – Research Report), with a ...

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the ...

CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...

CytomX Therapeutics is shrinking its headcount by 40% as the biotech regroups and looks at fresh ways to conserve cash.

Amgen Inc (AMGN) stock saw a decline, ending the day at $258.59 which represents a decrease of $-2.63 or -1.01% from the prior close of $261.22. The stock opened at $259.05 and touched a low of ...

Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...